Insulin Delivery: Still Waiting to Exhale
Executive Summary
After the commercial failure of Exubera, is inhaled insulin dead? Not at all. Exubera failed for very specific reasons: a cumbersome device, non-standard dosing, and no real clinical utility. The Exubera snafu has eroded the commercial value of inhaled insulin, but Nektar may be the best-positioned company currently competing in the inhaled insulin space. Nektar can afford to re-partner its version for less, because Pfizer has already paid for the bulk of the drug development work.
You may also be interested in...
Diabetes Device Market: Innovation Highlights Road to Growth
Despite the slumping economy, the diabetes market continues to be a very active area, with treatment-changing products recently launched or in late-stage development. Although no industry has been able to escape the effects of the US recession, and certain segments of the diabetes market have seen a decline in sales, other areas continue to move forward. Once the economy returns to healthier levels, the overall market is expected to see a renewal of growth. Meanwhile, an expanded emphasis on emerging international markets could help offset some of the sluggish numbers in the US and parts of Europe.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.